Angiomyolipoma medical therapy

Jump to navigation Jump to search

Angiomyolipoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Angiomyolipoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Angiomyolipoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Angiomyolipoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Angiomyolipoma medical therapy

CDC on Angiomyolipoma medical therapy

Angiomyolipoma medical therapy in the news

Blogs on Angiomyolipoma medical therapy

Directions to Hospitals Treating Angiomyolipoma

Risk calculators and risk factors for Angiomyolipoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2],Rekha, M.D.

Overview

Treatment options include selective renal artery embolization, nephron sparing surgery( enucleation or partial nephrectomy), complete and radical nephrectomy, radio-frequency ablation and everolimus. Treatment and management of the angiomyolipoma depends largely on

  1. Size of the tumors
  2. Signs and symptoms
  3. Presence or absence of Life threatening hemorrhage
  4. Its association with the tuberous sclerosis and
  5. The presence of the comorbidities.

Angiomyolipomas found incidentally, asymptomatic, < 4 cm in size, generally requires no intervention beside periodic evaluation. Medium sized lesion(4-8 cm) should be closely followed with the serial imaging studies(every 6 month and then yearly once stable) and elective intervention provided if the change in the size or symptoms noticed, to increases the chances of renal function salvage. Larger lesion(>8cm), shown to progress to the development of the complication so treated electively.

Medical Therapy

Everolimus, an mTOR inhibitor, is FDA approved for the treatment of angiomyolipomas. It is most commonly used in Tuberous sclerosis associated angiomyolipoma rather than sporadic cases. It has been shown to reduce the tumor volume as well as its risk of progression.[1][2]

Indications of Everolimus in Angiomyolipoma:

Patients with loss of renal function should be monitored for:

References

  1. Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM; et al. (2014). "The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1". Nephrol Dial Transplant. 29 (6): 1203–10. doi:10.1093/ndt/gfu013. PMC 4852219. PMID 24729041.
  2. Sooriakumaran P, Gibbs P, Coughlin G, Attard V, Elmslie F, Kingswood C; et al. (2010). "Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated". BJU Int. 105 (1): 101–6. doi:10.1111/j.1464-410X.2009.08649.x. PMID 19493268.
  3. Oesterling JE, Fishman EK, Goldman SM, Marshall FF (1986). "The management of renal angiomyolipoma". J Urol. 135 (6): 1121–4. PMID 3520013.
  4. Dickinson M, Ruckle H, Beaghler M, Hadley HR (1998). "Renal angiomyolipoma: optimal treatment based on size and symptoms". Clin Nephrol. 49 (5): 281–6. PMID 9617489.

Template:WikiDoc Sources